Abstract:Skeletal muscle from aging individuals is smaller and weaker than muscle from younger adults, which is a condition referred to as “sarcopenia”. The etiology of sarcopenia is complex as many factors and cellular responses are likely to contribute to the onset and progression of the condition. Thus, a strategy that might favorably affect multiple cellular responses may be more likely to impart beneficial effects on aging skeletal muscle. Agmatine is a compound that has potential to lessen age‐related muscle loss. The synthesis of agmatine occurs in the body via the decarboxylation of arginine, a conditionally essential amino acid. Although the formation of agmatine occurs principally in neurons it is detected in several tissues including skeletal muscle. While ample data support the role of agmatine as a neuromodulator and neurotransmitter, other physiological roles of agmatine have been revealed in the literature. Mounting evidence indicates a beneficial role of agmatine administration on various disease states and conditions. Notably, agmatine may produce beneficial effects through the activation or de‐activation of various cell signaling pathways. Collectively, alteration of cell signaling cascades by agmatine shown to occur in non‐muscle cells and tissues could induce responses that may benefit aging skeletal muscle. Thus, the purpose of this pilot experiment was to obtain evidence that agmatine supplementation may attenuate the development of sarcopenia in aging rats. Ten, thirty‐two‐month old male F344xBN F1 rats were singly housed and provided with either agmatine sulfate (0.2–0.25%) dissolved in drinking water, or plain water for a period of 4 weeks. Solutions were replaced with fresh mixtures every 3–4 days. Following the 4‐week supplementation period, plantaris force measures were tested in situ by stimulation of the sciatic nerve. Immediately afterwards the muscle was harvested for biochemical analyses. Body mass, muscle mass, muscle peak tetanic tension, and protein levels of inducible nitric oxide synthase (iNOS), manganese superoxide dismutase (MnSOD), and peroxisome proliferator‐activated receptor gamma coactivator 1‐alpha (PGC1a) were obtained. Due to low sample size only descriptive statistics are reported. All values are reported as mean ± SD for control and agmatine supplemented groups, respectively. Average body mass (g) (467.6 ± 44.4, n=4; 476.0 ± 19.5, n=3), plantaris mass (g) (0.36 ± 0.06, n=4; 0.30 ± 0.02, n=3) and muscle mass/body mass ratio (mg/g) (0.77 ± 0.13, n=4; 0.62 ± 0.01, n=3) values were similar or appeared lower in agmatine supplemented animals. Average maximal force production of the plantaris appeared to be similar (Po/muscle mass) (751.3 ± 198.1, n=4; 776.2 ± 260.8, n=3) between groups. Expression of iNOS (1.11 ± 0.96, n=5; 1.85 ± 1.53, n=4), PGC1a (0.16 ± 0.13, n=5; 0.22 ± 0.22, n=4) and MnSOD (4.82 ± 0.91, n=5; 5.05 ± 1.37, n=3) were either similar between the groups or slightly greater in agmatine supplemented rats, but low sample size likely affected variability of these measures. Our preliminary findings suggest that 4 weeks of agmatine administration does not favorably alter the functional or biochemical response of skeletal muscle in aging rats. Support or Funding Information Support by the Syracuse University SOE This abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.

Unacylated Ghrelin Protects Against Age‐Related Loss of Muscle Mass and Contractile Dysfunction in Skeletal Muscle

Protective Effects of Ghrelin on Fasting-Induced Muscle Atrophy in Aging Mice

Unacylated Ghrelin Reduces Skeletal Muscle Reactive Oxygen Species Generation and Inflammation and Prevents High-Fat Diet–Induced Hyperglycemia and Whole-Body Insulin Resistance in Rodents

Effects of Exogenous Ghrelin on Muscle Atrophy in Elderly Mice

Effects of Agmatine Exposure on Skeletal Muscle of Aging Rats

GABA Prevents Sarcopenia by Regulation of Muscle Protein Degradation and Inflammaging in 23‐ to 25‐Month‐Old Female Mice

The Green Tea Polyphenol Epigallocatechin-3-Gallate (EGCg) Attenuates Skeletal Muscle Atrophy in a Rat Model of Sarcopenia

Challenging Sarcopenia: Exploring AdipoRon in Aging Skeletal Muscle as a Healthspan-Extending Shield

Alverine citrate promotes myogenic differentiation and ameliorates muscle atrophy

Unacylated ghrelin restores insulin and autophagic signaling in skeletal muscle of diabetic mice

AAV‐Mediated nuclear localized PGC1α4 delivery in muscle ameliorates sarcopenia and aging‐associated metabolic dysfunctions

The Panax ginseng Berry Extract and Soluble Whey Protein Hydrolysate Mixture Ameliorates Sarcopenia-Related Muscular Deterioration in Aged Mice

Synergistically Acting on Myostatin and Agrin Pathways Increases Neuromuscular Junction Stability and Endurance in Old Mice

AAV-Mediated Nuclear Localized PGC14 Delivery in Muscle Ameliorates Sarcopenia and Aging-Associated Metabolic Dysfunctions

Late-life oral supplementation with apigenin mitigates loss of skeletal muscle strength and mass, exercise intolerance, and frailty with aging in mice

Protective Effects of Cervus elaphus and Eucommia ulmoides Mixture (KGC01CE) on Muscle Loss and Function in Aged Rats

Synergistic Effects of MFG-E8 and Whey Protein on Mitigating D-Galactose-induced Sarcopenia Through PI3K/AKT/PGC-1α and MAPK/ERK Signaling Pathways

Acetyl genistin modulates myotube differentiation and attenuates dexamethasone-induced muscle atrophy through the FoxO1/3 signaling pathway in C2C12 myotubes

Glucocorticoid intermittence coordinates rescue of energy and mass in aging-related sarcopenia through the myocyte-autonomous PGC1alpha-Lipin1 transactivation

Amelioration of muscle wasting by glucagon‐like peptide‐1 receptor agonist in muscle atrophy

GW8510 Alleviated Muscle Atrophy and Skeletal Muscle Dysfunction in Mice Through AMPK/PGC1α Signaling